Oral Session 2-9B CML: Clinical trials

[OS2-9B-4] Additional chromosomal abnormalities at diagnosis and their impact on treatment response in CML

Maho Ishikawa¹, Noriyoshi Iriyama², Michihide Tokuhira³, Tomoiku Takaku⁴, Eriko Sato⁵, Keiji Sugimoto⁶, Tomonori Nakazato⁷, Eisaku Iwanaga⁸, Hiroyuki Fujita⁹, Yuta Kimura³, Isao Fujioka⁴, Norio Komatsu⁴, Norio Asou¹, Masahiro Kizaki³, Yoshihiro Hatta², Tatsuya Kawaguchi¹⁰ (1.Dept. Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan., 2.Division of Hematology and Rheumatology, Nihon University, Tokyo, Japan, 3.Dept. Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 4.Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan, 5.Division of Hematology, Juntendo University Nerima Hospital, Tokyo, Japan, 6.Department of Hematology, Juntendo University Urayasu Hospital, Urayasu, Japan, 7.Department of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan, 8.Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan, 9.Department of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan, 10.Kumamoto Health Science University, Kumamoto, Japan)